Physician profile
June Kim
NPI 1205975240
$2,678.67
in general payments reported to CMS, 2019-2025
29 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $97.82 · 2021: $155 · 2022: $434 · 2023: $339 · 2024: $546 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $266.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $217.15 | 2019-2025 | Dupixent |
| Incyte Corporation | $209.13 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $143.00 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $116.41 | 2022-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $109.05 | 2019-2025 | |
| Amgen INC. | $98.16 | 2022-2024 | Otezla |
| Janssen Biotech, INC. | $93.39 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $93.38 | 2022-2025 | |
| Ucb, INC. | $73.41 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $68.82 | 2022 | |
| Pfizer INC. | $63.56 | 2019-2022 | |
| Genentech USA, INC. | $48.49 | 2019-2022 | |
| Merz North America, INC. | $45.64 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $38.94 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.83 | 2019 | |
| Sientra, INC. | $37.04 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.74 | 2025 | Spevigo |
| Organogenesis INC. | $34.73 | 2023 | Puraply |
| Mimedx Group, INC. | $30.43 | 2025 | |
| Celgene Corporation | $23.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.38 | 2024 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $22.22 | 2019 | |
| Biofrontera INC. | $20.05 | 2025 | |
| Smith+Nephew, INC. | $18.84 | 2021 | |
| Dermavant Sciences, INC. | $18.57 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $18.54 | 2024 | Zoryve |
| Oyster Point Pharma, INC. | $17.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw June Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.